Sequences of oligonucleotide aptamers for specifically recognizing radiation-sensitive protein CDKN1A and detection method
Through the microplate detection method of specific oligonucleotide aptamers and CDKN1A protein, the problem of long detection time of CDKN1A protein is solved, and rapid and sensitive radiation dose evaluation and cell aging identification are achieved, which is suitable for a variety of detection methods. .
Patent Information
- Application Number
- CN202411159447.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-22
AI Technical Summary
Existing CDKN1A protein detection methods such as Western Blot detection time cannot meet the needs of rapid assessment of the subjected dose and identification of cellular senescence.
A set of oligonucleotide aptamer sequences and microplate detection methods specifically identifying the radiation-sensitive protein CDKN1A were developed, and the presence of CDKN1A protein was incubated with the target protein by combining the denaturing nucleic acid sequence, and the presence of CDKN1A protein was determined through chromogenic reagents, which shortened the detection time. Until 4 hours.
The same results as Western Blot detection sensitivity is achieved, but the detection time is greatly shortened, and aptamers can be used in a variety of detection methods, including IP, immunofluorescence and EIS electrical impedance sensors, improving detection sensitivity and applicability.
Smart Images

Figure CN118910065A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of protein detection, and in particular relates to a group of sequences and a detection method of oligonucleotide aptamers that specifically recognize a radiation-sensitive protein CDKN1A. Background Art
[0002] SELEX (Systematic Evolution of Ligands by Exponential Enrichment) has been developed since the 1990s and has become an indispensable research tool. Its basic principle is based on the complementary pairing of single-stranded oligonucleotide bases to form advanced spatial structures, which are used to specifically bind to target molecules. Generally, 10 14 -10 15 The oligonucleotide library is almost enough to cover all possible structures. After multiple rounds of screening combined with PCR amplification, high-affinity nucleic acid aptamers will be screened. Compared with antibodies, aptamers have similar affinity and specificity. However, aptamers are low-cost, stable, easy to synthesize, and can be chemically modified at will. Therefore, aptamers are hailed as ideal antibody-like diagnostic reagents and potential substitutes.
[0003] With the rapid development of nuclear technology, its potential threat to the environment and human health is also increasing. In the case of nuclear and radiation accidents, accurate estimation of personnel exposure dose is the key to effectively treat the wounded. It is not only the basis of clinical diagnosis and treatment, but also an important reference for long-term effect evaluation. In the case of an accident, the use of physical dosimeters is limited because they cannot be popularized to everyone or the exposure dose exceeds the range. At this time, the biological dosimeter that uses some biological changes caused by the exposure of the exposed person to estimate the exposure dose can more accurately reflect the individual's true dose and personal sensitivity differences. CDKN1A protein is an expression protein with a radiation dose-effect relationship. At present, many literatures have reported that CDKN1A protein can be related to cell cycle regulation in the early stage of DNA damage. By detecting the expression of CDKN1A protein in the body of the exposed person, the exposure dose of the exposed person can be evaluated, providing a reference for subsequent treatment. At the same time, CDKN1A protein is related to cell senescence. It can be used as a cell senescence molecule Maker to identify the activation of the cell senescence pathway. A: Currently, the only detection method for CDKN1A protein as an indicator of radiation damage and cell aging is Western Blot detection, which takes a long time. Summary of the invention
[0004] The present invention provides a group of sequences and detection methods of oligonucleotide aptamers that specifically recognize radiation-sensitive protein CDKN1A, which shorten the detection time to 4 hours while ensuring the detection sensitivity.
[0005] The present invention provides a group of oligonucleotide aptamers that specifically recognize the radiation-sensitive protein CDKN1A. The nucleotide sequences of the oligonucleotide aptamers are shown in SEQ ID No.1 and SEQ ID No.2.
[0006] Preferably, the method further comprises modifying the oligonucleotide adaptor.
[0007] The present invention also provides the use of the above oligonucleotide aptamer in preparing a kit for detecting the radiation sensitive protein CDKN1A.
[0008] Preferably, the kit includes an aptamer microplate detection kit, an IP (Immunoprecipitation) detection kit, an immunofluorescence detection kit, an aptamer combined with an EIS electrical impedance sensor detection kit or an aptamer combined with a nanogold colorimetric detection kit.
[0009] The present invention also provides an aptamer microplate detection kit, comprising the above-mentioned oligonucleotide aptamer, a microplate, a coating buffer, a buffer, a blocking solution and a color developing reagent.
[0010] Preferably, the color developing reagent includes streptavidin-HRP reagent and TMB color developing solution.
[0011] The present invention also provides a method for detecting radiation-sensitive protein CDKN1A using a microplate, comprising the following steps: (1) dissolving the above oligonucleotide aptamer in a buffer solution and then denaturing it to obtain a denatured nucleic acid sequence;
[0012] (2) adding the denatured nucleic acid sequence described in step (1) to a microplate coated with the target protein and incubating together;
[0013] (3) After incubation, discard the liquid in the wells and add colorimetric reagent. 450 The value determines whether the target protein contains the radiation-sensitive protein CDKN1A.
[0014] Preferably, the oligonucleotide adaptor in step (1) further comprises chemical modification.
[0015] Preferably, the chemically modified oligonucleotide aptamer is dissolved in an incubation buffer and denatured at 95-100° C. for 5-10 min; the incubation buffer comprises a PBS buffer containing 1-5 mM MgCl 2 .
[0016] Preferably, the temperature of the co-incubation in step (2) is room temperature to 37° C., and the time is 30 to 60 minutes.
[0017] Beneficial effects: The present invention screened two specific aptamers for the radiation-sensitive protein CDKN1A by SELEX technology for the first time, and the nucleotide sequence of the oligonucleotide aptamer is shown in SEQ ID No.1 or SEQ ID No.2. It has been identified that the two oligonucleotide aptamers of the present invention can specifically recognize CDKN1A protein without binding to other unrelated proteins. The present invention also uses the principle of microplate detection to establish a new CDKN1A protein detection method, which can be used for radiation dose assessment and cell senescence identification.
[0018] The aptamer microplate method for detecting CDKN1A protein developed by the present invention has the same sensitivity as the conventional Western Blot detection method, and shortens the detection time to 4 hours. In addition, the aptamer of the present invention has potential for the development of other detection methods. The aptamer sequence is chemically modified, and different methods can be combined to improve the detection sensitivity and increase the applicability, such as carrying out IP detection, immunofluorescence detection and other detection methods, and the synthesis cost is low; for high-sensitivity detection, the aptamer can be combined with an EIS electrical impedance sensor; if visual detection without equipment is required, the aptamer combined with a nano-gold colorimetric detection method can be used. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The figure is a comparison of the binding ability between the CDKN1A aptamer sequence and the CDKN1A protein and other unrelated proteins;
[0020] Figure 2 The figure shows the result of P2103 competing with P2102 for binding to CDKN1A protein;
[0021] Figure 3 This is a diagram showing the results of P2102 competing with P2103 for binding to CDKN1A protein;
[0022] Figure 4 This is the affinity test result of P2102H and P2103 sequences with CDKN1A. DETAILED DESCRIPTION
[0023] The present invention provides a group of oligonucleotide aptamers that specifically recognize the radiation-sensitive protein CDKN1A. The nucleotide sequence of the oligonucleotide aptamer is shown as SEQ ID No.1 or SEQ ID No.2.
[0024] The present invention preferably screens two specific oligonucleotide aptamers for CDKN1A protein based on SELEX technology, and their sequences are as follows:
[0025] P2102 (SEQ ID No. 1): GCAATGGGTACGGTACTTCCGGTGCCGGTGG GGGAAGGGCTGGGTGGGACAAAAGTGCACGCTACTTTGCTAA;
[0026] P2103 (SEQ ID No. 2): GCAATGGGTACGGTACTTCCGGGTGGGCGGGA GGTGGGAGGTGGTGGAATCAAAAGTGCACGCTACTTTGCTAA;
[0027] P2101 (SEQ ID No. 3): GCAATGGGTACGGTACTTCCTCGTGGGTTTGCT GGGGTGGGTGGTGGGTCCAAAAGTGCACGCTACTTTGCTAA.
[0028] The present invention can modify the oligonucleotide aptamer, such as chemical modification. The biotinylation modification is used as an example for illustration in the embodiments, but it cannot be regarded as the entire protection scope of the present invention.
[0029] The present invention also provides the use of the above oligonucleotide aptamer in preparing a kit for detecting the radiation sensitive protein CDKN1A.
[0030] The oligonucleotide aptamers of the present invention can specifically recognize CDKN1A protein and do not bind to other unrelated proteins. Therefore, the oligonucleotide aptamers can be used to detect CDKN1A protein, such as IP (Immunoprecipitation) detection, immunofluorescence detection, aptamer combined with EIS electrical impedance sensor detection method, and aptamer combined with nanogold colorimetric detection method, etc., to achieve qualitative and / or quantitative detection of CDKN1A protein. Therefore, they can be used to construct kits corresponding to various detection methods, including aptamer microplate detection kits, IP (Immunoprecipitation) detection kits, immunofluorescence detection kits, aptamer combined with EIS electrical impedance sensor detection kits or aptamer combined with nanogold colorimetric detection kits.
[0031] The present invention also provides an aptamer microplate detection kit, comprising the above-mentioned oligonucleotide aptamer, a microplate, a coating buffer, a buffer, a blocking solution and a color developing reagent.
[0032] The microplate detection kit of the present invention can be used to qualitatively detect whether CDKN1A exists in the target protein, and during the detection, the target protein needs to be coated on the microplate, preferably including mixing the target protein with the coating buffer, adding it to the microplate, and incubating at 37°C for 2 hours; then washing each well with the buffer, adding the blocking solution after washing, and blocking at room temperature for 30 minutes to complete the coating of the target protein. The coating buffer of the present invention is preferably a 0.05M carbonate buffer with a pH value of 9.6. The buffer of the present invention is preferably a PBS buffer containing 5mM MgCl2; the blocking solution is preferably a 1% BSA solution.
[0033] The present invention utilizes the incubation buffer in the kit to dissolve the oligonucleotide aptamer, wherein the incubation buffer is preferably a PBS buffer containing 1-5mM MgCl2; the color developing reagent preferably includes streptavidin-coupled HRP reagent and TMB color developing solution.
[0034] The present invention also provides a method for detecting radiation-sensitive protein CDKN1A using a microplate, comprising the following steps: (1) dissolving the above oligonucleotide aptamer in a buffer solution and then denaturing it to obtain a denatured nucleic acid sequence;
[0035] (2) adding the denatured nucleic acid sequence described in step (1) to a microplate coated with the target protein and incubating together;
[0036] (3) After incubation, discard the liquid in the wells and add colorimetric reagent. 450 The value determines whether the target protein contains the radiation-sensitive protein CDKN1A.
[0037] The present invention preferably denatures the chemically modified oligonucleotide aptamer after dissolving it in a buffer to obtain a denatured nucleic acid sequence, wherein the chemical modification preferably includes biotin labeling. In the embodiment, the biotin-labeled oligonucleotide aptamer is dissolved in an incubation buffer and denatured at 95-100° C. for 5-10 minutes; the incubation buffer includes a PBS buffer containing 1-5 mM MgCl2. After the denaturation is completed, the present invention is immediately placed on ice to be fully cooled.
[0038] The present invention preferably incubates the above-mentioned denatured nucleic acid sequence with a microplate coated with a target protein, wherein the coating preferably includes mixing the protein to be detected in a coating buffer (0.05M carbonate buffer, pH9.6), adding 100 μL / well to the microplate, and incubating at 37°C for 2 hours; washing each well with 200 μL of PBS-MgCl2 buffer, repeating the washing 5 times, adding 200 μL of blocking solution (1% BSA), and blocking at room temperature for 30 minutes.
[0039] In the present invention, the denatured sequence (600 ng) is preferably added to a microplate to incubate the nucleic acid sequence and the protein together, and the incubation temperature is preferably room temperature and the time is preferably 30 minutes. The room temperature in the present invention preferably refers to 26°C.
[0040] The present invention performs color development after the co-incubation. First, the liquid in the wells after the co-incubation is discarded, and each well is washed with 200 μL of PBS-MgCl2 buffer, and the washing is repeated 5 times. After the last washing, the liquid in the wells must be completely absorbed; 100 μL of streptavidin-coupled HRP reagent diluted according to 1:1000 is added to each well, and the plate is incubated at room temperature to 37°C for 30 to 60 minutes, and the liquid in the well is discarded, and the plate is washed 5 times, and the method is the same as above; 100 μL of TMB color development solution is added to each well, and color is developed at room temperature in the dark. When there is an obvious color change, 100 μL of stop solution is added, and the enzyme-linked instrument OD450nm wavelength reading is read. If the OD450nm wavelength reading is increased compared with the control protein group or the blank group, it means that the target protein is detected.
[0041] To further illustrate the present invention, the sequences and detection methods of a group of oligonucleotide aptamers that specifically recognize the radiation-sensitive protein CDKN1A provided by the present invention are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0042] Example 1
[0043] Comparison of binding ability between CDKN1A aptamers and CDKN1A protein and other unrelated proteins
[0044] (1) Synthesize biotin-labeled aptamer sequences (P2102, SEQ ID No. 1; P2103, SEQ ID No. 2) and control sequences (P2101, SEQ ID No. 3).
[0045] (2) 1 μg of the protein to be detected was mixed in coating buffer (0.05 M carbonate buffer, pH 9.6), added to the microplate at 100 μL / well, and incubated at 37°C for 2 hours. The proteins to be detected were CDKN1A, PIG3, AKT2, and EGFR, and the Ensembl genome browser IDs were ENSG00000124762, ENSG00000115129, ENSG00000105221, and ENSG00000146648, respectively.
[0046] (3) Each well was washed with 200 μL of PBS-MgCl2 buffer, and the washing was repeated 5 times. 200 μL of blocking solution (1% BSA) was added and blocked at room temperature for 30 min.
[0047] (4) Dissolve the biotin-labeled P2101, P2102 or P2103 sequence in incubation buffer (1×PBS-5 mM MgCl2), denature at 100°C for 5 min, and immediately place on ice to cool thoroughly.
[0048] (5) The denatured sequence (600 ng) was added to the microplate, and the nucleic acid sequence and protein were incubated together at room temperature for 30 min.
[0049] (6) Discard the liquid in the wells and wash each well with 200 μL of PBS-MgCl2 buffer. Repeat the wash five times. After the last wash, completely drain the liquid in the wells.
[0050] (7) Add 100 μL of streptavidin-HRP reagent diluted 1:1000 to each well, incubate at room temperature for 30 min, discard the liquid in the well, and wash the plate 5 times using the same method as above.
[0051] (8) Add 100 μL of TMB colorimetric solution to each well and develop the color at room temperature in the dark. When there is a clear color change, add 100 μL of stop solution and read the OD at 450 nm using an enzyme-linked immunosorbent assay.
[0052] The results are as follows Figure 1 As shown, P2102 and P2103 have good binding affinity with CDKN1A protein, while the control sequence has no binding affinity with CDKN1A protein, and the P2102 and P2103 sequences have no binding affinity with other proteins.
[0053] Example 2
[0054] P2102 or P2103 competition binding assay
[0055] (1) Synthesize biotin-labeled and unlabeled P2102 or P2103 aptamer sequences.
[0056] (2) 1 μg of the protein to be detected was mixed with coating buffer (0.05 M carbonate buffer, pH 9.6), added to the microplate at 100 μL / well, and incubated at 37°C for 2 hours.
[0057] (3) Each well was washed with 200 μL of PBS-MgCl2 buffer, and the washing was repeated 5 times. 200 μL of blocking solution (1% BSA) was added and blocked at room temperature for 30 min.
[0058] (4) Dissolve the biotin-labeled P2102 or P2103 sequence in incubation buffer (1×PBS-5 mM MgCl2), denature at 100°C for 5 min, and immediately place on ice to cool thoroughly.
[0059] (5) 600 ng of the denatured sequence was added to the microplate, and the nucleic acid sequence and protein were incubated together at room temperature for 30 min.
[0060] (6) Discard the liquid in the wells and wash each well with 200 μL of PBS-MgCl2 buffer. Repeat the wash five times. After the last wash, completely drain the liquid in the wells.
[0061] (7) Add 1, 5, 10, or 50 times of the unlabeled P2102 or P2103 sequence and incubate the nucleic acid sequence with the corresponding sequence to compete for binding at room temperature for 30 min.
[0062] (8) Discard the liquid in the wells and wash each well with 200 μL of PBS-MgCl2 buffer. Repeat the wash five times. After the last wash, completely drain the liquid in the wells.
[0063] (9) Add 100 μL of streptavidin-HRP reagent diluted 1:1000 to each well, incubate at room temperature for 30 min, discard the liquid in the well, and wash the plate 5 times using the same method as above.
[0064] (10) Add 100 μL of TMB colorimetric solution to each well and develop the color at room temperature in the dark. When there is a clear color change, add 100 μL of stop solution and read the OD at 450 nm using an enzyme-linked immunosorbent assay.
[0065] The results are as follows Figure 2 and Figure 3 As shown, P2102 and P2103 have a weak competitive relationship with the CDKN1A protein binding site, suggesting that their binding sites are different but may have structural similarities.
[0066] Example 3
[0067] Affinity detection of oligonucleotide aptamer sequences and CDKN1A
[0068] The BLI device added different concentration gradients of CDKN1A protein including 0, 2.6, 4, 5.9, 8.9, 13.3, 20 μg / mL and P2102 or P1203 1.13 μg / mL aptamers into the BLI device reaction plate wells, and through the reaction steps of equilibration for 600 s, baseline drawing for 120 s, protein fixation for 300 s, baseline drawing for 120 s, binding for 400 s, and dissociation for 120 s, the interference signal on the membrane surface was detected at the same time, and the dissociation constant was calculated by fitting the curve. The results are shown in Figure 4 As shown, the dissociation constant between P2102 and CDKN1A protein is 2.04E-011M, and the dissociation constants between P2103 and CDKN1A protein are 2.04E-011M and 2.21E-07M.
[0069] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A group of oligonucleotide aptamers that specifically recognize the radiation-sensitive protein CDKN1A, It is characterized in that The nucleotide sequences of the oligonucleotide adaptors are shown in SEQ ID No.1 and SEQ ID No.
2.
2. The oligonucleotide aptamer according to claim 1, It is characterized in that It also includes modifying the oligonucleotide aptamer.
3. Use of the oligonucleotide aptamer according to claim 1 or 2 in preparing a kit for detecting the radiation-sensitive protein CDKN1A.
4. The use according to claim 3, It is characterized in that The types of the kit include at least one of the following: an aptamer microplate detection kit, an Immunoprecipitation detection kit, an immunofluorescence detection kit, an aptamer combined with an EIS electrical impedance sensor detection kit, or an aptamer combined with a nanogold colorimetric detection kit.
5. An aptamer microplate detection kit, It is characterized in that The method comprises the oligonucleotide aptamer according to claim 1 or 2, a microplate, a coating buffer, a buffer, a blocking solution and a color developing reagent.
6. The aptamer microplate detection kit according to claim 5, It is characterized in that The color developing reagent comprises a streptavidin-coupled HRP reagent and a TMB color developing solution.
7. A method for detecting radiation-sensitive protein CDKN1A using a microplate, It is characterized in that The following steps are involved: (1) dissolving the oligonucleotide aptamer according to claim 1 or 2 in a buffer and then denaturing it to obtain a denatured nucleic acid sequence; (2) adding the denatured nucleic acid sequence described in step (1) to a microplate coated with the target protein and incubating together; (3) After incubation, discard the liquid in the wells and add colorimetric reagent. 450 The value determines whether the target protein contains the radiation-sensitive protein CDKN1A.
8. The method according to claim 7, It is characterized in that The oligonucleotide adaptor in step (1) further includes chemical modification.
9. The method according to claim 8, It is characterized in that The method comprises dissolving the chemically modified oligonucleotide aptamer in an incubation buffer and denaturing the oligonucleotide aptamer at 95-100°C for 5-10 minutes; the incubation buffer comprises 1-5 mM MgCl 2 PBS buffer.
10. The method according to claim 7, It is characterized in that The temperature of the co-incubation in step (2) is from room temperature to 37° C., and the time is 30 to 60 minutes.
Citation Information
Patent Citations
Aptamer and application in preparing medicine or product for treating leukaemia thereof
CN103409428A
Methods of cancer treatment using ATR inhibitor
CN111526889A
Oligonucleotide aptamer for specifically recognizing radiation-sensitive protein TP53I3, kit and detection method
CN115725587A
Methods of diagnosing and treating polycystic ovarian syndrome (PCOS)
CN116917502A
Biomarkers for assessing exposure to ionizing radiation and absorbed dose
WO2011127056A2
